Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
Location: United States, Connecticut, New Haven
Member count: 11-50
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Axial VC | axialvc.co... |
| 24.02.2022 | SR One | srone.com |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 31.01.2022 | The metave... | This is the web version of Ter... | - | - | fortune.co... |
| 31.01.2022 | The metave... | This is the web version of Ter... | - | - | fortune.co... |
| 31.01.2022 | Simcha The... | Simcha Therapeutics, a New Hav... | USA | - | finsmes.co... |
| 25.06.2020 | Simcha The... | NEW HAVEN, CT, Simcha Therap... | - | - | vcnewsdail... |